Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02337062 · ClinicalTrials.gov registry record · Phase 3

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

A Phase 3 study of PONV, sponsored by Acacia Pharma.

Completed
Registry status
Phase 3
Development phase
1,147
Enrollment target
20
Study locations

NCT02337062 is a Phase 3 study of PONV that has completed, run by Acacia Pharma. The registered enrollment target is 1,147 participants, above the 166-participant average among 3 other PONV trials with a reported enrollment target (591% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02337062, a Phase 3 study of PONV, has completed, sponsored by Acacia Pharma.

COMPLETED
Registry status
Phase 3
Development phase
1,147 participants
Enrollment target
20
Study locations

Study Summary

A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG APD421

Study Locations (20)

Other

  • University Hospital - Besançon
  • Centre Hospitalier Lyon-Sud - Lyon
  • Centre Hospitalier de Mulhouse - Mulhouse
  • Hopital Foch - Paris
  • CHU de Hautepierre - Strasbourg
  • HELIOS Klinikum Aue - Aue

Texas

  • First Street Surgical Center - Bellaire
  • Victory Medical Center Houston - Houston
  • Memorial Hermann-Memorial City Hospital - Houston

New York

  • Albany Medical Center Hospital - Albany
  • Stony Brook Medicine - Stony Brook

North Carolina

  • Duke University Medical Center - Durham
  • Wake Forest University School of Medicine - Winston-Salem

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio State University - Columbus

Alabama

  • Helen Keller Hospital - Sheffield

California

  • UCSF School of Medicine - San Francisco

Florida

  • Jackson Memorial Hospital - Miami

Trial Details

FieldValue
Enrollment Target 1,147 participants
Start Date 2015-02
Est. Completion 2015-09
Phase Phase 3

Sponsor

Acacia Pharma

9 total trials

What the Registry Record Tells You About NCT02337062

The ClinicalTrials.gov registry entry for NCT02337062 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,147 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 166-participant average among 3 other PONV trials with a reported enrollment target (591% higher). The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PONV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02337062 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, New York.

Frequently Asked Questions

What is clinical trial NCT02337062 about?

NCT02337062 is a clinical study titled "Phase IIIb Study of APD421 in Combination as PONV Prophylaxis". A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).

What is the current status of trial NCT02337062?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,147 participants. The study started on 2015-02. Estimated completion is 2015-09.

What conditions does trial NCT02337062 study?

This clinical trial studies the following conditions: PONV.

What interventions are being tested in trial NCT02337062?

The interventions under investigation include: Placebo (DRUG), APD421 (DRUG).

Who is sponsoring clinical trial NCT02337062?

This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02337062 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PONV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.